A citation-based method for searching scientific literature

Jason J Luke, Piotr Rutkowski, Paola Queirolo, Michele Del Vecchio, Jacek Mackiewicz, Vanna Chiarion-Sileni, Luis de la Cruz Merino, Muhammad A Khattak, Dirk Schadendorf, Georgina V Long, Paolo A Ascierto, Mario Mandala, Federica De Galitiis, Andrew Haydon, Reinhard Dummer, Jean-Jacques Grob, Caroline Robert, Matteo S Carlino, Peter Mohr, Andrew Poklepovic, Vernon K Sondak, Richard A Scolyer, John M Kirkwood, Ke Chen, Scott J Diede, Sama Ahsan, Nageatte Ibrahim, Alexander M M Eggermont. Lancet 2022
Times Cited: 5







List of co-cited articles
15 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino,[...]. J Clin Oncol 2020
93
60

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Jeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, Vernon K Sondak, Georgina V Long, Merrick I Ross, Alexander J Lazar, Mark B Faries, John M Kirkwood, Grant A McArthur,[...]. CA Cancer J Clin 2017
60

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Alexander M M Eggermont, Christian U Blank, Mario Mandalà, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino,[...]. Lancet Oncol 2021
57
40

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, John M Kirkwood, Vanna Chiarion Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux,[...]. N Engl J Med 2020
105
40

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona M McNeil, Michal Lotem,[...]. Lancet Oncol 2019
434
40

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni,[...]. Lancet Oncol 2020
147
40

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Kenneth F Grossmann, Megan Othus, Sapna P Patel, Ahmad A Tarhini, Vernon K Sondak, Michael V Knopp, Teresa M Petrella, Thach-Giao Truong, Nikhil I Khushalani, Justine V Cohen,[...]. Cancer Discov 2022
4
50

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
Alexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, Christian U Blank, Mario Mandala, Georgina V Long, Catherine Barrow, Anna Maria Di Giacomo, Rosalie Fisher, Shahneen Sandhu,[...]. Eur J Cancer 2021
5
40

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, Michael Fluck, Thomas Eigentler, Carmen Loquai, Sebastian Haferkamp, Ralf Gutzmer, Friedegund Meier, Peter Mohr,[...]. Lancet 2020
96
40

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy.
C N Owen, A N Shoushtari, D Chauhan, D J Palmieri, B Lee, M W Rohaan, J Mangana, V Atkinson, F Zaman, A Young,[...]. Ann Oncol 2020
27
40

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, Alexander C Huang, Michael T Tetzlaff, Bart A van de Wiel, Serigne Lo, Ahmad A Tarhini, Elizabeth M Burton, Thomas E Pennington,[...]. Nat Med 2021
81
40

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards,[...]. N Engl J Med 2016
815
40

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Georgina V Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon,[...]. N Engl J Med 2017
745
40

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. N Engl J Med 2019
40

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
Mark B Faries, John F Thompson, Alistair J Cochran, Robert H Andtbacka, Nicola Mozzillo, Jonathan S Zager, Tiina Jahkola, Tawnya L Bowles, Alessandro Testori, Peter D Beitsch,[...]. N Engl J Med 2017
655
40

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Elisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, Chandra Adhikari, Carolien Bierman, Bart A van de Wiel, Richard A Scolyer, Oscar Krijgsman, Karolina Sikorska, Hanna Eriksson,[...]. Lancet Oncol 2019
188
20

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
Felicity Newell, Ines Pires da Silva, Peter A Johansson, Alexander M Menzies, James S Wilmott, Venkateswar Addala, Matteo S Carlino, Helen Rizos, Katia Nones, Jarem J Edwards,[...]. Cancer Cell 2022
8
20

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J Crabb, Michiel S Van Der Heijden, Bernadett Szabados, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz,[...]. Nat Med 2019
214
20

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
Prachi Bhave, Lalit Pallan, Georgina V Long, Alexander M Menzies, Victoria Atkinson, Justine V Cohen, Ryan J Sullivan, Vanna Chiarion-Sileni, Marta Nyakas, Katharina Kahler,[...]. Br J Cancer 2021
11
20

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry,[...]. Cell 2016
20

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.
Jing Liu, Stephen J Blake, Michelle C R Yong, Heidi Harjunpää, Shin Foong Ngiow, Kazuyoshi Takeda, Arabella Young, Jake S O'Donnell, Stacey Allen, Mark J Smyth,[...]. Cancer Discov 2016
375
20

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Joris L Vos, Joris B W Elbers, Oscar Krijgsman, Joleen J H Traets, Xiaohang Qiao, Anne M van der Leun, Yoni Lubeck, Iris M Seignette, Laura A Smit, Stefan M Willems,[...]. Nat Commun 2021
8
20

Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Mathieu Rouanne, Dean F Bajorin, Raquibul Hannan, Matthew D Galsky, Stephen B Williams, Andrea Necchi, Padmanee Sharma, Thomas Powles. Eur Urol Oncol 2020
32
20

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
Reinhard Dummer, Jan C Brase, James Garrett, Catarina D Campbell, Eduard Gasal, Matthew Squires, Daniel Gusenleitner, Mario Santinami, Victoria Atkinson, Mario Mandalà,[...]. Lancet Oncol 2020
53
20

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
M T Tetzlaff, J L Messina, J E Stein, X Xu, R N Amaria, C U Blank, B A van de Wiel, P M Ferguson, R V Rawson, M I Ross,[...]. Ann Oncol 2018
73
20

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.
Nick van Dijk, Alberto Gil-Jimenez, Karina Silina, Kees Hendricksen, Laura A Smit, Jeantine M de Feijter, Maurits L van Montfoort, Charlotte van Rooijen, Dennis Peters, Annegien Broeks,[...]. Nat Med 2020
98
20

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
Daniel J Olson, Zeynep Eroglu, Bruce Brockstein, Andrew S Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, Mario Velasco, Jose Lutzky, Emily Higgs,[...]. J Clin Oncol 2021
24
20

Preferences for Immunotherapy in Melanoma: A Systematic Review.
Ann Livingstone, Anupriya Agarwal, Martin R Stockler, Alexander M Menzies, Kirsten Howard, Rachael L Morton. Ann Surg Oncol 2020
21
20

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
Christian U Blank, Elisa A Rozeman, Lorenzo F Fanchi, Karolina Sikorska, Bart van de Wiel, Pia Kvistborg, Oscar Krijgsman, Marlous van den Braber, Daisy Philips, Annegien Broeks,[...]. Nat Med 2018
353
20

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
Georgina V Long, Jean-Jacques Grob, Paul Nathan, Antoni Ribas, Caroline Robert, Dirk Schadendorf, Stephen R Lane, Carmen Mak, Philippe Legenne, Keith T Flaherty,[...]. Lancet Oncol 2016
193
20

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D Wolchok, Anthony M Joshua, Antoni Ribas, F Stephen Hodi, Omid Hamid, Caroline Robert,[...]. Clin Cancer Res 2018
147
20

Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
Michele Maio, Christian Blank, Andrea Necchi, Anna Maria Di Giacomo, Ramy Ibrahim, Michael Lahn, Bernard A Fox, R Bryan Bell, Giampaolo Tortora, Alexander M M Eggermont. Eur J Cancer 2021
7
20

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S Carlino,[...]. N Engl J Med 2018
884
20

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.
Meredith M Regan, Lillian Werner, Sumati Rao, Komal Gupte-Singh, F Stephen Hodi, John M Kirkwood, Harriet M Kluger, James Larkin, Michael A Postow, Corey Ritchings,[...]. J Clin Oncol 2019
30
20

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo Antonio Ascierto, Jon M Richards,[...]. Eur J Cancer 2019
76
20

The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
Anne Zaremba, Alexander M M Eggermont, Caroline Robert, Reinhardt Dummer, Selma Ugurel, Elisabeth Livingstone, Paolo A Ascierto, Georgina V Long, Dirk Schadendorf, Lisa Zimmer. Eur J Cancer 2021
11
20

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Myriam Chalabi, Lorenzo F Fanchi, Krijn K Dijkstra, José G Van den Berg, Arend G Aalbers, Karolina Sikorska, Marta Lopez-Yurda, Cecile Grootscholten, Geerard L Beets, Petur Snaebjornsson,[...]. Nat Med 2020
276
20

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
Hojabr Kakavand, James S Wilmott, Alexander M Menzies, Ricardo Vilain, Lauren E Haydu, Jennifer H Yearley, John F Thompson, Richard F Kefford, Peter Hersey, Georgina V Long,[...]. Clin Cancer Res 2015
102
20

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, Helen J Gogas, Ana M Arance, C Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion-Sileni, Ivan Marquez-Rodas,[...]. N Engl J Med 2017
20

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
Georgina V Long, Robyn P M Saw, Serigne Lo, Omgo E Nieweg, Kerwin F Shannon, Maria Gonzalez, Alexander Guminski, Jenny H Lee, Hansol Lee, Peter M Ferguson,[...]. Lancet Oncol 2019
66
20

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Amod A Sarnaik, Omid Hamid, Nikhil I Khushalani, Karl D Lewis, Theresa Medina, Harriet M Kluger, Sajeve S Thomas, Evidio Domingo-Musibay, Anna C Pavlick, Eric D Whitman,[...]. J Clin Oncol 2021
31
20

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux,[...]. J Clin Oncol 2018
132
20

A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
Jinxiu Li, Timothy S Mulvihill, Li Li, Jared J Barrott, Mary L Nelson, Lena Wagner, Ian C Lock, Amir Pozner, Sydney Lynn Lambert, Benjamin B Ozenberger,[...]. Cancer Discov 2021
6
20

Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
Andrea Necchi, Daniele Raggi, Andrea Gallina, Russell Madison, Maurizio Colecchia, Roberta Lucianò, Rodolfo Montironi, Patrizia Giannatempo, Elena Farè, Filippo Pederzoli,[...]. Eur Urol 2020
136
20

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
E A Rozeman, E P Hoefsmit, I L M Reijers, R P M Saw, J M Versluis, O Krijgsman, P Dimitriadis, K Sikorska, B A van de Wiel, H Eriksson,[...]. Nat Med 2021
59
20

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards,[...]. Lancet Oncol 2015
778
20

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Alexander C Huang, Michael A Postow, Robert J Orlowski, Rosemarie Mick, Bertram Bengsch, Sasikanth Manne, Wei Xu, Shannon Harmon, Josephine R Giles, Brandon Wenz,[...]. Nature 2017
835
20

Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners.
Ann Livingstone, Donna Milne, Kathy Dempsey, Danielle Marie Muscat, Alexander M Menzies, Kirsten Howard, Martin R Stockler, Rachael L Morton. Patient 2021
3
33

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko,[...]. N Engl J Med 2019
473
20

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Axel Hauschild, James Larkin, Antoni Ribas, Brigitte Dréno, Keith T Flaherty, Paolo A Ascierto, Karl D Lewis, Edward McKenna, Qian Zhu, Yong Mun,[...]. JAMA Oncol 2018
43
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.